
USD
+$0.00
(+0.00%
)At Close (As of Nov 14, 2025)
$6.05B
Market Cap
8.76
P/E Ratio
8.6
EPS
$76.80
52 Week High
$35.95
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $749M |
| Total Revenue | $807M |
| Cost Of Revenue | $57M |
| Costof Goods And Services Sold | $57M |
| Operating Income | -$303M |
| Selling General And Administrative | $301M |
| Research And Development | $534M |
| Operating Expenses | $1.1B |
| Investment Income Net | - |
| Net Interest Income | -$167M |
| Interest Income | - |
| Interest Expense | $167M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $76M |
| Income Before Tax | -$363M |
| Income Tax Expense | $176K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$363M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$196M |
| Ebitda | -$120M |
| Net Income | -$363M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.7B |
| Total Current Assets | $1.4B |
| Cash And Cash Equivalents At Carrying Value | $780M |
| Cash And Short Term Investments | $780M |
| Inventory | $23M |
| Current Net Receivables | $159M |
| Total Non Current Assets | $339M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $119M |
| Intangible Assets Excluding Goodwill | $119M |
| Goodwill | $82M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $360M |
| Other Current Assets | $44M |
| Other Non Current Assets | - |
| Total Liabilities | $2.8B |
| Total Current Liabilities | $581M |
| Current Accounts Payable | $17M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $271M |
| Total Non Current Liabilities | $2.2B |
| Capital Lease Obligations | $104M |
| Long Term Debt | $2.1B |
| Current Long Term Debt | $258M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $2.5B |
| Other Current Liabilities | $282M |
| Other Non Current Liabilities | $21M |
| Total Shareholder Equity | -$1.1B |
| Treasury Stock | - |
| Retained Earnings | -$3.6B |
| Common Stock | $77K |
| Common Stock Shares Outstanding | $77M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$108M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $76M |
| Capital Expenditures | $74M |
| Change In Receivables | - |
| Change In Inventory | $6.2M |
| Profit Loss | - |
| Cashflow From Investment | $44M |
| Cashflow From Financing | $256M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$363M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $749M |
| Total Revenue | $807M |
| Cost Of Revenue | $57M |
| Costof Goods And Services Sold | $57M |
| Operating Income | -$303M |
| Selling General And Administrative | $301M |
| Research And Development | $534M |
| Operating Expenses | $1.1B |
| Investment Income Net | - |
| Net Interest Income | -$167M |
| Interest Income | - |
| Interest Expense | $167M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $76M |
| Income Before Tax | -$363M |
| Income Tax Expense | $176K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$363M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$196M |
| Ebitda | -$120M |
| Net Income | -$363M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
PTC Therapeutics, Inc. is a leading biopharmaceutical company headquartered in South Plainfield, New Jersey, specializing in the development of innovative therapies for rare genetic disorders. With a strong emphasis on RNA modulation and small molecule therapeutics, PTC has built a compelling pipeline of product candidates that address critical unmet medical needs. The company's commitment to transformative treatments establishes it as a significant player in the rare disease market, where its pioneering solutions aim to enhance patient outcomes and address the challenges faced by those with serious, underserved conditions.